381 related articles for article (PubMed ID: 29797659)
1. Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia.
Oberley MJ; Gaynon PS; Bhojwani D; Pulsipher MA; Gardner RA; Hiemenz MC; Ji J; Han J; O'Gorman MRG; Wayne AS; Raca G
Pediatr Blood Cancer; 2018 Sep; 65(9):e27265. PubMed ID: 29797659
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia.
Moskop A; Pommert L; Thakrar P; Talano J; Phelan R
Pediatr Blood Cancer; 2021 Jan; 68(1):e28739. PubMed ID: 33009894
[TBL] [Abstract][Full Text] [Related]
3. [Identification of TCF3-ZNF384 fusion by transcriptome sequencing in B cell acute lymphoblastic leukemia and its laboratory and clinical characteristics].
Wu Q; Wang F; Yang J; Chen X; Ma X; Cao P; Zhang Y; Nie D; Chen J; Zhou X; Fang J; Liu M; Zhang M; Wu P; Wang T; Liu H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Apr; 38(4):351-354. PubMed ID: 33834463
[TBL] [Abstract][Full Text] [Related]
4. Frequency and outcome of pediatric acute lymphoblastic leukemia with ZNF384 gene rearrangements including a novel translocation resulting in an ARID1B/ZNF384 gene fusion.
Shago M; Abla O; Hitzler J; Weitzman S; Abdelhaleem M
Pediatr Blood Cancer; 2016 Nov; 63(11):1915-21. PubMed ID: 27392123
[TBL] [Abstract][Full Text] [Related]
5. ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype.
Hirabayashi S; Ohki K; Nakabayashi K; Ichikawa H; Momozawa Y; Okamura K; Yaguchi A; Terada K; Saito Y; Yoshimi A; Ogata-Kawata H; Sakamoto H; Kato M; Fujimura J; Hino M; Kinoshita A; Kakuda H; Kurosawa H; Kato K; Kajiwara R; Moriwaki K; Morimoto T; Nakamura K; Noguchi Y; Osumi T; Sakashita K; Takita J; Yuza Y; Matsuda K; Yoshida T; Matsumoto K; Hata K; Kubo M; Matsubara Y; Fukushima T; Koh K; Manabe A; Ohara A; Kiyokawa N;
Haematologica; 2017 Jan; 102(1):118-129. PubMed ID: 27634205
[TBL] [Abstract][Full Text] [Related]
6. Leukemia With
Lin N; Yan X; Cai D; Wang L
Front Oncol; 2021; 11():709036. PubMed ID: 34395283
[TBL] [Abstract][Full Text] [Related]
7. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.
Gardner R; Wu D; Cherian S; Fang M; Hanafi LA; Finney O; Smithers H; Jensen MC; Riddell SR; Maloney DG; Turtle CJ
Blood; 2016 May; 127(20):2406-10. PubMed ID: 26907630
[TBL] [Abstract][Full Text] [Related]
8. Successful Treatment of TCF3-HLF-positive Childhood B-ALL with Chimeric Antigen Receptor T-Cell Therapy.
Wang T; Wan X; Yang F; Shi W; Liu R; Ding L; Tang Y; Luo C; Yang X; Ma Y; Wang X; Liang H; Li B; Lu J; Chen J
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):386-392. PubMed ID: 33640284
[TBL] [Abstract][Full Text] [Related]
9. Very late relapse cases of TCF3-ZNF384-positive acute lymphoblastic leukemia.
Nishimura A; Hasegawa D; Hirabayashi S; Kanabuchi S; Yamamoto K; Aiga S; Nishitani M; Hosoya Y; Noguchi Y; Ohki K; Kiyokawa N; Mori S; Manabe A
Pediatr Blood Cancer; 2019 Nov; 66(11):e27891. PubMed ID: 31347769
[No Abstract] [Full Text] [Related]
10. Zinc finger protein 384 (
Sudutan T; Erbilgin Y; Hatirnaz Ng O; Karaman S; Karakas Z; Kucukcankurt F; Celkan T; Timur C; Ozdemir GN; Hacısalihoglu S; Gelen SA; Sayitoğlu M
Leuk Lymphoma; 2022 Dec; 63(12):2931-2939. PubMed ID: 35921545
[TBL] [Abstract][Full Text] [Related]
11. Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy.
Semchenkova A; Mikhailova E; Komkov A; Gaskova M; Abasov R; Matveev E; Kazanov M; Mamedov I; Shmitko A; Belova V; Miroshnichenkova A; Illarionova O; Olshanskaya Y; Tsaur G; Verzhbitskaya T; Ponomareva N; Bronin G; Kondratchik K; Fechina L; Diakonova Y; Vavilova L; Myakova N; Novichkova G; Maschan A; Maschan M; Zerkalenkova E; Popov A
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409391
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
[TBL] [Abstract][Full Text] [Related]
13. EP300-ZNF384 fusion gene product up-regulates GATA3 gene expression and induces hematopoietic stem cell gene expression signature in B-cell precursor acute lymphoblastic leukemia cells.
Yaguchi A; Ishibashi T; Terada K; Ueno-Yokohata H; Saito Y; Fujimura J; Shimizu T; Ohki K; Manabe A; Kiyokawa N
Int J Hematol; 2017 Aug; 106(2):269-281. PubMed ID: 28378055
[TBL] [Abstract][Full Text] [Related]
14. CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report.
Wen S; Niu Z; Xing L; Wang Y; Li H; Kuang N; Luo J; Zhang X; Wang F
BMC Cancer; 2018 Nov; 18(1):1143. PubMed ID: 30458755
[TBL] [Abstract][Full Text] [Related]
15. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
16. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against
Niswander LM; Graff ZT; Chien CD; Chukinas JA; Meadows CA; Leach LC; Loftus JP; Kohler ME; Tasian SK; Fry TJ
Haematologica; 2023 Feb; 108(2):457-471. PubMed ID: 35950535
[TBL] [Abstract][Full Text] [Related]
17.
Britten O; Ragusa D; Tosi S; Kamel YM
Cells; 2019 Oct; 8(11):. PubMed ID: 31671855
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
Front Immunol; 2018; 9():239. PubMed ID: 29515572
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia.
Mo G; Wang HW; Talleur AC; Shahani SA; Yates B; Shalabi H; Douvas MG; Calvo KR; Shern JF; Chaganti S; Patrick K; Song Y; Fry TJ; Wu X; Triplett BM; Khan J; Gardner RA; Shah NN
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33246985
[TBL] [Abstract][Full Text] [Related]
20. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
